Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16070733 | 1.00 | AOC3 (0.38) | AOC3HDAC8PYGLMAPTALDH1A1 | |
| SCHEMBL16070677 | 0.89 | AOC3 (0.33) | AOC3HDAC8PYGLALDH1A1KDM4E | |
| SCHEMBL17521197 | 0.82 | HDAC8 (0.34) | AOC3HDAC8ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL16070703 | 0.81 | APP (0.33) | — | |
| SCHEMBL13849426 | 0.79 | LMNA (0.54) | AOC3HDAC8MAPTALDH1A1HTR1A | |
| SCHEMBL17518200 | 0.79 | LMNA (0.54) | AOC3HDAC8MAPTALDH1A1HTR1A | |
| SCHEMBL26931788 | 0.78 | SCN4A (0.39) | HDAC8 | |
| SCHEMBL26648121 | 0.78 | SCN4A (0.39) | HDAC8 | |
| SCHEMBL26648119 | 0.78 | SCN4A (0.39) | HDAC8 | |
| SCHEMBL28039508 | 0.77 | ACACB (0.38) | AOC3PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190054179-A1 | NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20170296503-A1 | METHOD FOR USING NOVEL HYDROXAMIC ACID DERIVATIVE AND ANTIBACTERIAL SUBSTANCE IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170290918-A1 | NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHICAL CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290918-A1 | NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC7A1, SLC16A1 | AOC3 4630/4885HDAC8 209/4885PYGL 1241/4885 |
| US-20170296503-A1 | METHOD FOR USING NOVEL HYDROXAMIC ACID DERIVATIVE AND ANTIBACTERIAL SUBSTANCE IN COMBINATION | EGLN2, NGLY1, NAAA | AOC3 4092/4885HDAC8 125/4885PYGL 2039/4885 |
| US-20190054179-A1 | NOVEL PHARMACEUTICAL COMPOSITION CONTAINING HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | HAAO, HPD, HCAR2 | AOC3 4258/4885HDAC8 929/4885PYGL 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.